Biotech
Natera
Natera raises $200M Series E at $2.75B valuation
San Carlos, CAJuly 31, 20191 min read
Total Raised
$200M
Valuation
$2.75B
Latest Round
Series E
Employees
2000+
Natera: Series E Funding Round
Natera has successfully raised $200M in Series E funding, reaching a valuation of $2.75B.
Company Overview
Cell-free DNA testing for cancer and pregnancy
Funding Details
The Series E round was led by Perceptive Advisors, with participation from Goldman Sachs.
Company Information
- Headquarters: San Carlos, CA
- Founded: 2003
- Employees: 2000+
- Category: Biotech
Investment
Natera plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Perceptive Advisors: Verified investor in Series E
- Goldman Sachs: Verified investor in Series E
Company Info
Headquarters
San Carlos, CA
Founded
2003
Team Size
2000+
Last Round
$200M(Jul 2019)
Investors (2)
P
Perceptive AdvisorsLeadLead Investor
Verified investor in Series E
G
Goldman SachsInvestor
Verified investor in Series E
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free